Tentative identification of a labetalol metabolite in the investigation of a false-positive amphetamine immunoassay result using targeted and untargeted high-resolution mass spectrometry

OBJECTIVES: Immunoassays are widely used for urine drug screening in hospital and emergency departments, but assay-dependent cross-reactivity may produce false-positive results. Labetalol and its metabolites have previously been associated with false-positive amphetamine immunoassay findings. We investigated an unexpected positive amphetamine screening result in a 45-year-old pregnant woman receiving labetalol. METHODS: The urine specimen was evaluated using two amphetamine immunoassay methods and subsequently investigated by ultrahigh-performance liquid chromatography-high-resolution tandem mass spectrometuy (UHPLC-HRMS/MS). Targeted HRMS was used to identify known compounds, whereas untargeted HRMS was applied to detect and prioritize unexpected features potentially relevant to the false-positive immunoassay result. Authentic reference standards, when available, were analyzed under identical LC-HRMS conditions to discriminate among relevant isobaric candidates. RESULTS: N feature for which 1-methyl-3-phenylpropylamine(3-amino-1-phenylbutane), a known minor labetalol metabolite, provided the highest spectral-library match. Phentermine and methamphetamine were among the isobaric candidates but were experimentally excluded by analysis of authentic standards. CONCLUSIONS: The contrasting immunoassay findings and HRMS results support an assay-dependent analytical interference and illustrate how targeted and untargeted HRMS can progressively refine the investigation of unexpected screening results. However, the tentatively identified labetalol metabolite candidate cannot be established as the cause of the nal von minden response without dedicated cross-reactivity experiments using a purified reference standard.

Authors

Institutions

Publication Details

Journal
Clinical Chemistry and Laboratory Medicine (CCLM)
Published
2026-11-16
DOI
https://doi.org/10.1515/cclm-2026-1205
Primary Topic
Forensic Toxicology and Drug Analysis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Tentative identification of a labetalol metabolite in the investigation of a false-positive amphetamine immunoassay result using targeted and untargeted high-resolution mass spectrometry

José Manuel Matey, Luis Manuel Menéndez-Quintanal, Jacobo J. Villacampa-Jiménez, Elene Laburu-Dañobeitia et al.
Clinical Chemistry and Laboratory Medicine (CCLM)
Forensic Toxicology and Drug Analysis
article

Tentative identification of a labetalol metabolite in the investigation of a false-positive amphetamine immunoassay result using targeted and untargeted high-resolution mass spectrometry

José Manuel Matey, Luis Manuel Menéndez-Quintanal, Jacobo J. Villacampa-Jiménez, Elene Laburu-Dañobeitia, Darío Cabana-Ramos, Sonali Karnani, Miguel Ángel Pico-Picos
article en

Abstract

OBJECTIVES: Immunoassays are widely used for urine drug screening in hospital and emergency departments, but assay-dependent cross-reactivity may produce false-positive results. Labetalol and its metabolites have previously been associated with false-positive amphetamine immunoassay findings. We investigated an unexpected positive amphetamine screening result in a 45-year-old pregnant woman receiving labetalol. METHODS: The urine specimen was evaluated using two amphetamine immunoassay methods and subsequently investigated by ultrahigh-performance liquid chromatography-high-resolution tandem mass spectrometuy (UHPLC-HRMS/MS). Targeted HRMS was used to identify known compounds, whereas untargeted HRMS was applied to detect and prioritize unexpected features potentially relevant to the false-positive immunoassay result. Authentic reference standards, when available, were analyzed under identical LC-HRMS conditions to discriminate among relevant isobaric candidates. RESULTS: N feature for which 1-methyl-3-phenylpropylamine(3-amino-1-phenylbutane), a known minor labetalol metabolite, provided the highest spectral-library match. Phentermine and methamphetamine were among the isobaric candidates but were experimentally excluded by analysis of authentic standards. CONCLUSIONS: The contrasting immunoassay findings and HRMS results support an assay-dependent analytical interference and illustrate how targeted and untargeted HRMS can progressively refine the investigation of unexpected screening results. However, the tentatively identified labetalol metabolite candidate cannot be established as the cause of the nal von minden response without dedicated cross-reactivity experiments using a purified reference standard.

Clinical Chemistry and Laboratory Medicine (CCLM)
Hospital Universitario de Canarias (ES), Instituto Nacional de Toxicología y Ciencias Forenses (ES)
Good health and well-being
Forensic Toxicology and Drug Analysis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon